Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 19/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dirocaftor SCHEMBL29389903 | 1.00 | CFTR (0.64) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Dirocaftor SCHEMBL29380859 | 1.00 | CFTR (0.64) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Dirocaftor SCHEMBL19438477 | 0.93 | CFTR (0.60) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Dirocaftor SCHEMBL29390858 | 0.93 | CFTR (0.60) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL29389626 | 0.90 | CFTR (0.71) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL19457017 | 0.90 | CFTR (0.60) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL19457020 | 0.90 | CFTR (0.71) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL29390870 | 0.90 | CFTR (0.60) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL19457016 | 0.90 | CFTR (0.62) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL29390590 | 0.90 | CFTR (0.62) | CFTRADORA3ADRB3TBXA2RSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3691638-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240368198-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240109922-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11248010-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11248010-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3440057-B1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3440057-B1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3691638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10662207-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662207-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190153000-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190153000-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2019-05-23 | — | — | US | disclosed |
| WO-2019071078-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019071078-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| EP-3440057-A1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | Proteostasis Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017177124-A1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017177124-A1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109922-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | CFTR 1/4885ADORA3 1518/4885ADRB3 1120/4885 |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, ATP5ME | CFTR 1/4885ADORA3 3244/4885ADRB3 2224/4885 |
| US-20240368198-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | CFTR 1/4885ADORA3 1518/4885ADRB3 1120/4885 |
| US-11248010-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | CFTR 1/4885ADORA3 1518/4885ADRB3 1120/4885 |
| US-20190153000-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | CFTR 1/4885ADORA3 1518/4885ADRB3 1120/4885 |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1A | CFTR 1/4885ADORA3 1391/4885ADRB3 1259/4885 |
| US-10662207-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | CFTR 1/4885ADORA3 1518/4885ADRB3 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.